BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37490181)

  • 1. SETD2 controls m6A modification of transcriptome and regulates the molecular oncogenesis of glioma.
    Kumari S; Singh M; Kumar S; Muthuswamy S
    Med Oncol; 2023 Jul; 40(9):249. PubMed ID: 37490181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. METTL3 exerts synergistic effects on m6A methylation and histone modification to regulate the function of VGF in lung adenocarcinoma.
    Shi K; Sa R; Dou L; Wu Y; Dong Z; Fu X; Yu H
    Clin Epigenetics; 2023 Sep; 15(1):153. PubMed ID: 37742030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer.
    Petri BJ; Klinge CM
    J Mol Endocrinol; 2023 Feb; 70(2):. PubMed ID: 36367225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of N6-methyladenosine modulators promote breast cancer progression.
    Wu L; Wu D; Ning J; Liu W; Zhang D
    BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the regulatory role of RNA methylation modifications in glioma.
    Long S; Yan Y; Xu H; Wang L; Jiang J; Xu Z; Liu R; Zhou Q; Huang X; Chen J; Li Z; Wei W; Li X
    J Transl Med; 2023 Nov; 21(1):810. PubMed ID: 37964279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusaric acid induces hepatic global m6A RNA methylation and differential expression of m6A regulatory genes
    Ghazi T; Nagiah S; Chuturgoon AA
    Epigenetics; 2022 Jun; 17(6):695-703. PubMed ID: 34517792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
    Kumari S; Muthusamy S
    Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer.
    Zhang C; Zhang M; Ge S; Huang W; Lin X; Gao J; Gong J; Shen L
    Cancer Med; 2019 Aug; 8(10):4766-4781. PubMed ID: 31243897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer.
    Ralser DJ; Condic M; Klümper N; Ellinger J; Staerk C; Egger EK; Kristiansen G; Mustea A; Thiesler T
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2417-2424. PubMed ID: 35731272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome-wide profiling identifies colon cancer-associated m6A transcripts and potential RNA methyl modifiers.
    Ramasamy D; Thippannah M; Maharajan HRP; Balaiah M; Seshadri RA; Kodous AS; Herceg Z; Mehta A; Rao AKDM; Mani S
    Mol Biol Rep; 2024 Feb; 51(1):299. PubMed ID: 38345740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SEDT2/METTL14-mediated m6A methylation awakening contributes to hypoxia-induced pulmonary arterial hypertension in mice.
    Zhou XL; Huang FJ; Li Y; Huang H; Wu QC
    Aging (Albany NY); 2021 Feb; 13(5):7538-7548. PubMed ID: 33658391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
    Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
    J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
    Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
    J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA m6A methylation across the transcriptome.
    Sendinc E; Shi Y
    Mol Cell; 2023 Feb; 83(3):428-441. PubMed ID: 36736310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
    Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
    J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A RNA methylation and beyond - The epigenetic machinery and potential treatment options.
    Garbo S; Zwergel C; Battistelli C
    Drug Discov Today; 2021 Nov; 26(11):2559-2574. PubMed ID: 34126238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk Between m6A RNA Methylation and miRNA Biogenesis in Cancer: An Unholy Nexus.
    Jayasree PJ; Dutta S; Karemore P; Khandelia P
    Mol Biotechnol; 2023 Oct; ():. PubMed ID: 37831403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
    Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
    J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.